Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A High-Potency Protein That Normalizes Body Weight in DIO Mice through Triple Agonism at FGF21, GLP1, and GIP Receptors.

Biochemistry·2026
Same author

The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron.

Science translational medicine·2024
Same author

Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.

Journal of internal medicine·2024
Same author

Activity-balanced GLP-1/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates.

Cell metabolism·2023
Same author

Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist.

Cell metabolism·2023
Same author

Structural determinants of dual incretin receptor agonism by tirzepatide.

Proceedings of the National Academy of Sciences of the United States of America·2022

Related Experiment Video

Updated: May 24, 2026

Affinity Precipitation of Active Rho-GEFs Using a GST-tagged Mutant Rho Protein (GST-RhoA(G17A)) from Epithelial Cell Lysates
11:28

Affinity Precipitation of Active Rho-GEFs Using a GST-tagged Mutant Rho Protein (GST-RhoA(G17A)) from Epithelial Cell Lysates

Published on: March 31, 2012

FGF21 as a therapeutic reagent.

Yang Zhao1, James D Dunbar, Alexei Kharitonenkov

  • 1Eli Lilly and Company, Indianapolis, IN, USA.

Advances in Experimental Medicine and Biology
|March 8, 2012
PubMed
Summary

Fibroblast Growth Factor 21 (FGF21) shows promise as a novel therapeutic for metabolic diseases like Type 2 diabetes and obesity. Its broad benefits and safety profile in animal models suggest significant potential for treating various metabolic abnormalities.

Area of Science:

  • Metabolic disease therapeutics
  • Protein therapeutics
  • Pharmacology

Background:

  • Rising global prevalence of obesity and Type 2 diabetes necessitates novel drug development.
  • Large molecule therapies, including insulin and incretin mimetics, have a history of success in diabetes management.
  • Several protein therapeutics are under investigation for metabolic disorders.

Purpose of the Study:

  • To review the potential of Fibroblast Growth Factor 21 (FGF21) as a therapeutic agent.
  • To discuss the in vitro biology, animal models, and in vivo pharmacology of FGF21.
  • To highlight FGF21's therapeutic applications for metabolic diseases.

Main Methods:

  • Review of in vitro studies on FGF21.
  • Analysis of genetic animal models relevant to metabolic diseases.

More Related Videos

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
09:36

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

Experimental Approaches for Biochemical Analysis of Glial Fibrillary Acidic Protein and Its Disease-associated Variants
06:02

Experimental Approaches for Biochemical Analysis of Glial Fibrillary Acidic Protein and Its Disease-associated Variants

Published on: November 28, 2025

Related Experiment Videos

Last Updated: May 24, 2026

Affinity Precipitation of Active Rho-GEFs Using a GST-tagged Mutant Rho Protein (GST-RhoA(G17A)) from Epithelial Cell Lysates
11:28

Affinity Precipitation of Active Rho-GEFs Using a GST-tagged Mutant Rho Protein (GST-RhoA(G17A)) from Epithelial Cell Lysates

Published on: March 31, 2012

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
09:36

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

Experimental Approaches for Biochemical Analysis of Glial Fibrillary Acidic Protein and Its Disease-associated Variants
06:02

Experimental Approaches for Biochemical Analysis of Glial Fibrillary Acidic Protein and Its Disease-associated Variants

Published on: November 28, 2025

  • Examination of in vivo pharmacological data for FGF21.

    • Main Results:

    • FGF21 demonstrates significant pharmacologic benefits across multiple metabolic abnormalities.
    • FGF21 has shown a lack of apparent side effects in various animal models.
    • FGF21 exhibits potential for treating Type 2 diabetes mellitus, obesity, dyslipidemia, cardiovascular disease, and fatty liver disease.

    Conclusions:

    • FGF21 is a highly promising candidate for treating a range of metabolic diseases.
    • Its efficacy and safety profile position FGF21 as a novel therapeutic reagent.
    • Further discussion will cover FGF21's biology, genetics, and pharmacology.